Cytosorbents COO buys 2,073 shares in market

Cytosorbents’ President and COO boosted his direct Common Stock position with open‑market purchases, alongside existing RSU awards and split‑adjusted share holdings.

Rhea-AI Filing Summary

Cytosorbents Corp (CTSO) reports that President and COO Vincent Capponi purchased Common Stock in open-market transactions on September 14, 2026, buying 1,800 shares at $6.07 per share and 273 shares at $5.90 per share, with no Rule 10b5-1 trading plan reported.

Capponi’s reported holdings include multiple tranches of RSUs that settle into Common Stock upon a Change in Control under the 2014 Long-Term Incentive Plan, time-based RSUs including 4,455 RSUs granted August 8, 2025 (2,228 unvested), and 25,736 shares of Common Stock owned, all figures reflecting the 1-for-20 reverse stock split effective September 8, 2026.

Insider Trade Summary

Net Buyer: 2,073 shares

Net Buy 2 txns

Insider Capponi Vincent

Role President and COO

Bought 2,073 shs ($13K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1, F2, F3, F4, F5	1,800	$6.07	$11K
Purchase	Common Stock F1, F2, F3, F4, F5	273	$5.90	$2K

Holdings After Transaction: Common Stock — 40,387 shares (Direct)

Footnotes (5)

1. F1. This transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person.
2. F2. Includes: (i) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Issuer") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 505 RSUs granted on March 15, 2018, (b) 895 RSUs granted on February 24, 2017, (c) 2,700 RSUs granted on June 7, 2016 and (d) 6,250 RSUs granted on April 8, 2015;
3. F3. (continued from footnote 2) (ii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 4,455 RSUs granted on August 8, 2025 and of which 2,228 remain unvested as of the date hereof; and
4. F4. (continued from footnote 3) (iii) 25,736 shares of Common Stock owned by the Reporting Person.
5. F5. Reflects the 1-for-20 reverse stock split effected by the Issuer on September 8, 2026.

Key Figures

Open-market purchase 1: 1,800 shares at $6.07 per share Open-market purchase 2: 273 shares at $5.90 per share Total shares bought: 2,073 shares +5 more

8 metrics

Open-market purchase 1 1,800 shares at $6.07 per share Common Stock purchased on September 14, 2026

Open-market purchase 2 273 shares at $5.90 per share Common Stock purchased on September 14, 2026

Total shares bought 2,073 shares Net open-market purchases reported on September 14, 2026

RSUs granted March 15, 2018 505 RSUs Settle into Common Stock upon a Change in Control

RSUs granted February 24, 2017 895 RSUs Settle into Common Stock upon a Change in Control

RSUs granted June 7, 2016 2,700 RSUs Settle into Common Stock upon a Change in Control

Time-based RSUs granted August 8, 2025 4,455 RSUs (2,228 unvested) Vest in two equal parts on first and second anniversaries

Common Stock owned 25,736 shares Shares of Common Stock owned by the reporting person

Key Terms

Restricted Stock Units, Change In Control, 1-for-20 reverse stock split, Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan

4 terms

Restricted Stock Units financial

"the following RSUs that will be settled into Common Stock upon vesting"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Change In Control financial

"RSUs that will be settled into Common Stock upon vesting upon a "Change In Control""

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

1-for-20 reverse stock split financial

"Reflects the 1-for-20 reverse stock split effected by the Issuer"

Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan financial

"as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider purchases did Cytosorbents (CTSO) report for Vincent Capponi?

Cytosorbents reported that President and COO Vincent Capponi purchased 1,800 shares at $6.07 and 273 shares at $5.90 of Common Stock on September 14, 2026 in open‑market transactions, according to the Form 4 filing.

Was a Rule 10b5-1 trading plan used for the CTSO insider transactions?

No. The filing indicates no Rule 10b5-1 trading plan was reported for Vincent Capponi’s September 14, 2026 open‑market purchases of Cytosorbents Common Stock.

What RSU awards does the CTSO President and COO currently have?

The filing notes RSUs that settle upon a Change in Control (including grants of 505, 895, 2,700, and 6,250 RSUs) and a time‑based grant of 4,455 RSUs on August 8, 2025, of which 2,228 remain unvested.

How many Cytosorbents (CTSO) shares does Vincent Capponi own directly?

Footnotes state that Vincent Capponi owns 25,736 shares of Common Stock of Cytosorbents Corporation, in addition to his RSU awards, with amounts stated on a split‑adjusted basis.

How did Cytosorbents’ 1-for-20 reverse stock split affect this Form 4?

A footnote explains that the figures in the Form 4 reflect the 1-for-20 reverse stock split effected by Cytosorbents Corporation on September 8, 2026, meaning share and RSU amounts are presented on a split‑adjusted basis.

What are the vesting terms of the 2025 RSU grant reported for CTSO’s President and COO?

The 4,455 RSUs granted on August 8, 2025 vest in equal parts on the first and second anniversaries of the grant date, subject to Vincent Capponi’s continued service, and will settle into shares of Common Stock upon vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 04:06 PM Accepted by SEC EDGAR 09/16/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Capponi Vincent

(Last) (First) (Middle)

C/O CYTOSORBENTS CORPORATION

305 COLLEGE ROAD EAST

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cytosorbents Corp [ CTSO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and COO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/14/2026		P		1,800(1)	A	$6.07	40,114(2)(3)(4)(5)	D
Common Stock	09/14/2026		P		273(1)	A	$5.9	40,387(2)(3)(4)(5)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person.

2. Includes: (i) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Issuer") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 505 RSUs granted on March 15, 2018, (b) 895 RSUs granted on February 24, 2017, (c) 2,700 RSUs granted on June 7, 2016 and (d) 6,250 RSUs granted on April 8, 2015;

3. (continued from footnote 2) (ii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 4,455 RSUs granted on August 8, 2025 and of which 2,228 remain unvested as of the date hereof; and

4. (continued from footnote 3) (iii) 25,736 shares of Common Stock owned by the Reporting Person.

5. Reflects the 1-for-20 reverse stock split effected by the Issuer on September 8, 2026.

	/s/ Peter J. Mariani attorney-in-fact Vincent Capponi	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)